1 Personalized structural biology reveals the molecular mechanisms underlying

heterogeneous epileptic phenotypes caused by de novo KCNC2 variants 2

3

4 **Authors**

- 5
- Souhrid Mukherjee^{1,6}, Thomas A. Cassini^{11,#}, Ningning Hu^{8,9,#}, Tao Yang^{5,#}, Bian Li^{1,5,6,#}, Wangzhen Shen⁸, Christopher W. Moth⁶, David C. Rinker^{4,6}, Jonathan H. Sheehan^{6,10}, Joy D. 6
- 7 Cogan², Undiagnosed Diseases Network, John H. Newman³, Rizwan Hamid², Robert L.
- Macdonald^{5,8}, Dan M. Roden^{5,7,15} Jens Meiler^{4,5,6,7,12,13,14}, Georg Kuenze^{4,6,12*}, John A. Phillips 8
- III^{2*}, John A. Capra^{1,6,7,15,16*} 9

10

- 11 ¹Department of Biological Sciences, Vanderbilt University, Nashville, TN 37235, USA.
- 12 13 ²Department of Pediatrics, Division of Medical Genetics and Genomic Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
- 14 ³Pulmonary Hypertension Center, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University 15 Medical Center, Nashville, TN 37232, USA.
- 16 17 ⁴Department of Chemistry, Vanderbilt University, Nashville, TN 37235, USA.
- ⁵Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232. USA.
- ⁶Center for Structural Biology, Vanderbilt University, Nashville, TN 37235, USA.
- ⁷Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA,
- ⁸Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- ⁹Department of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- 18 19 20 21 22 23 24 25 26 27 28 29 30 ¹⁰John T. Milliken Department of Internal Medicine, Washington University School of Medicine, St. Louis MO, 63110, USA.
- ¹¹Department of Internal Medicine, National Institutes of Health Clinical Center, Bethesda, MD 20814, USA.
- ¹²Institute for Drug Discovery, Leipzig University Medical School, Leipzig, SAC 04103, Germany.
- ¹³Department of Chemistry, Leipzig University, Leipzig, SAC 04109, Germany.
- ¹⁴Department of Computer Science, Leipzig University, Leipzig, SAC 04109, Germany.
- ¹⁵Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- ¹⁶Bakar Computational Health Sciences Institute and Department of Epidemiology and Biostatistics, University of 31 California, San Francisco, CA 94143, USA.
- 32
- 33 [#] Equal contribution
- 34 * Correspondence: georg.kuenze@uni-leipzig.de, john.a.phillips@vumc.org, tony@capralab.org

35 36 **Keywords**

- 37 developmental and epileptic encephalopathy (DEE), KCNC2, de novo variant, molecular
- 38 dynamics (MD) simulations, electrophysiology, personalized structural biology

2	q
9	2

- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51

52

53

54 ABSTRACT

- 55 Background. Next-generation whole exome sequencing (WES) is ubiquitous as an early step in
- 56 the diagnosis of rare diseases and the interpretation of variants of unknown significance (VUS).
- 57 Developmental and epileptic encephalopathies (DEE) are a group of rare devastating
- 58 epilepsies, many of which have unknown causes. Increasing WES in the clinic has identified
- 59 several rare monogenic DEEs caused by ion channel variants. However, WES often fails to
- 60 provide actionable insight, due to the challenges of proposing functional hypotheses for
- 61 candidate variants. Here, we describe a "personalized structural biology" (PSB) approach that
- 62 addresses this challenge by leveraging recent innovations in the determination and analysis of
- 63 protein 3D structures.
- 64 *Results.* We illustrate the power of the PSB approach in an individual from the Undiagnosed
- 65 Diseases Network (UDN) with DEE symptoms who has a novel de novo VUS in KCNC2
- 66 (p.V469L), the gene that encodes the Kv3.2 voltage-gated potassium channel. A nearby KCNC2
- 67 variant (p.V471L) was recently suggested to cause DEE-like phenotypes. We find that both
- variants are located in the conserved hinge region of the S6 helix and likely to affect protein
- 69 function. However, despite their proximity, computational structural modeling suggests that the
- 70 V469L variant is likely to sterically block the channel pore, while the V471L variant is likely to
- 51 stabilize the open state. Biochemical and electrophysiological analyses demonstrate
- heterogeneous loss-of-function and gain-of-function effects, respectively, as well as differential
- inhibition in response to 4-aminopyridine (4-AP) treatment. Using computational structural
- 74 modeling and molecular dynamics simulations, we illustrate that the pore of the V469L variant is
- more constricted increasing the energetic barrier for K^+ permeation, whereas the V471L variant
- 76 stabilizes the open conformation
- 77 Conclusions. Our results implicate KCNC2 as a causative gene for DEE and guided the
- 78 interpretation of a UDN case. They further delineate the molecular basis for the heterogeneous
- clinical phenotypes resulting from two proximal pathogenic variants. This demonstrates how the
- 80 PSB approach can provide an analytical framework for individualized hypothesis-driven
- 81 interpretation of protein-coding VUS suspected to contribute to disease.
- 82

83 INTRODUCTION

- 84 The advent of cheaper and more accurate DNA sequencing technologies has enabled the
- 85 integration of genetic information into diverse areas of medicine. For example, more than 70%
- 86 of rare diseases are thought to have a genetic cause, and recent efforts have identified the
- 87 causal variants for thousands of Mendelian diseases ^{1–3}. However, causal variants have not
- been identified for approximately half (~3000) of known rare genetic diseases ^{4–6}, and
- 89 sequencing often fails to lead to actionable insights, even after expert clinical evaluation through
- 90 programs like the NIH's Undiagnosed Diseases Network (UDN) ^{7–9}.
- 91 Many computational methods have been developed for interpreting variants observed in
- 92 clinical sequencing $^{10-13}$. However, they have substantial weaknesses and often disagree $^{14-18}$.
- 93 In particular, commonly used tools provide only ill-defined, categorical variant classifications like
- 94 "pathogenic" and "benign" and fail to propose specific hypotheses about the underlying
- 95 molecular effects of variants. A prediction that a variant is "pathogenic" is not of much clinical

96 use without a testable prediction of the mechanisms of its pathogenicity, pleiotropic effects and97 possible insights to treatment.

Motivated by the challenges of variant interpretation, recent advances in experimental 98 approaches for protein structure determination ^{19–24} and recent improvements to the accuracy of 99 prediction, modeling and analysis of native 3D protein structural models ^{25–28}, we propose a new 100 variant interpretation paradigm. Our "personalized structural biology" approach focuses on 101 102 making mechanistic predictions about the effects of the variant(s) observed in patients in the 103 context of their genetic background via computational and experimental evaluation of protein 104 structure and function. We demonstrate the power of this approach on two candidate VUS in 105 KCNC2, the gene encoding the homo-tetrameric voltage gated potassium channel Kv3.2, one 106 variant from an individual with an unsolved epilepsy-like disease enrolled in the UDN and another variant from a recent case report ²⁹ with epilepsy-like phenotypes; however no 107 functional validation was done for the variant. 108

109 Developmental epileptic encephalopathies (DEE) are a group of devastating disorders in 110 which epileptic activity contributes to cognitive and behavior impairment in addition to underlying 111 developmental pathologies ^{30,31}. Genetic etiologies are thought to be the cause of a substantial proportion of these DEE cases, and with recent advances in genetic testing technology, many 112 DEE variants have been discovered. The underlying genetic mechanisms are diverse ³², but 113 defects in neuronal ion channels are thought to be a common cause of DEE. For example, the 114 initial discovery that Dravet syndrome is caused by variants in SCN1A³³ has been followed by 115 116 the demonstration that variants in many voltage-gated potassium (Kv) channels can cause 117 DEE^{34} . The largest family of these channels is the Kv family, with 12 subfamilies whose alpha subunits are encoded by approximately 40 genes. The Kv3 subfamily influences rapid firing of 118 inhibitory interneurons in the central nervous system ³⁵. The general mechanism of Kv3.2 119 120 channel gating is thought to be similar to other closely related voltage-gated potassium ion channels. Ky channels consist of four homologous subunits, with each monomer having six 121 transmembrane helical domains (S1-S6). S1-S4 form the voltage sensing domain (VSD) and 122 S5-S6 from all four subunits form the membrane pore. A linker domain between S4 and S5 123 connects the VSD to the pore forming units ^{36–40}. The VSD undergoes conformational changes 124 between the open and closed state of the channel ⁴¹, and the coupling between the S4-S5 linker 125 and the S6 pore forming unit is responsible for the voltage dependent gating of the channel ^{42,43}. 126 127 With a pronounced inward movement of the positively charged S4 voltage sensor, the S4-S5 linker is pushed downwards, which causes the S6 helix to constrict the pore, thus closing the 128 channel ³⁹. This gating mechanism is made possible by the presence of a Proline-Valine-Proline 129 130 (PVP) motif, which acts as a hinge domain in the S6 helix. The hinge domain allows the S6 131 pore-forming helix to kink at the flexible PVP motif to open and close the channel pore.

132 Other members of this subfamily have been implicated as a potential causes of DEE and other epilepsy-like symptoms with discoveries of variants in genes encoding Kv3.1 and Kv3.3^{44–} 133 ⁴⁶. More recently variants in *KCNC2*, which is highly expressed in GABAergic interneurons in 134 135 the CNS, have been suggested to be linked to DEE-like phenotypes, with possibly dominant negative effects ^{29,47,48}. However, the links and their mechanisms are yet to be established. 136 137 Our work makes four main contributions. First, we demonstrate via expression and 138 electrophysiology analyses that the two candidate KCNC2 variants (p.V469L, p.V471L) have 139 loss-of-function and gain-of-function effects, respectively, despite both affecting the essential

- 140 hinge region of Kv3.2 responsible for channel gating. Second, our protein structural modeling
- and molecular dynamics simulations rationalize the mechanistic basis for the phenotypic
- 142 heterogeneity of these variants. Third, our results combine to validate links between KCNC2
- 143 variants and heterogenous DEE phenotypes. Finally, our analyses provide a blueprint for
- 144 integrating genetics, expression analysis, electrophysiology, and protein structural modeling to
- 145 develop mechanistic understanding of the molecular effects of *de novo* variants in rare disease.
- 146

147 **RESULTS**

148

149 Undiagnosed Diseases Network patient with DEE-like symptoms

150 A child (3-8 years old) at the Vanderbilt University UDN site presented with DEE-like 151 phenotypes, including multiple types of refractory seizure and global developmental delay. At a 152 very young age, they developed generalized tonic clonic seizures, and was diagnosed with 153 Lennox-Gastaut syndrome, a severe form of DEE. However, they continued to have frequent 154 myoclonic absence seizures and occasional generalized tonic clonic seizure. The IRB of the 155 National Institutes of Health (NIH) gave ethical approval for this work (protocol 15HG0130). The 156 participants' or their legal representatives' have consented to IRB 15HG0130 and allowed the 157 results of this research work to be published. A full clinical report is available upon contacting 158 the corresponding authors.

- Initial sequencing of the individual on an epilepsy gene panel through Athena covered *ARHGEF9, ARX, CDKL5, CNTNAP2, FOXG1, GABRG2, GRIN2A, KCNT1, MECP2, NRXN1, PCDH19, PNKP, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, SCN1A, SCN1B, SCN2A, SCN8A, SCN9A, SLC25A22, SLC2A1, SLC9AC, SPTAN1, STXBP1, SYNGAP1, TCF4, TREX1, UBE3A, ZEB2.* The only potentially significant finding was a heterozygous c.2985G>C
 variant in *GRIN2A*. Deletion analysis of *SCN1A* was negative as well. Secondary findings,
 metabolic screens, and mitochondrial DNA sequencing were also negative.
- 166 Following the negative epilepsy panel result, WES revealed a candidate variant in a 167 voltage-gated potassium channel Kv3.2, KCNC2 c.1405G>T (p.V469L). Sanger sequencing 168 confirmed this variant. This variant was not seen in either of his parents, and therefore it was 169 presumed to be *de novo*. This variant is in the conserved hinge motif of the channel which is 170 critical for channel gating (**Figure 1**). The potential relevance of this variant is supported by 171 another recently reported discovered candidate heterozygous variant also located in the hinge 172 domain of KCNC2 (c.1411G>C, p.V471L) only two amino acids away from V469L variant found in our UDN subject ²⁹. Our UDN subject and the previously reported case shared the 173 174 phenotypes of DEE, seizures refractory to medications, developmental delay, and microcephaly. 175 However, their phenotypes differed in that the reported case also had complete absence of 176 speech, dystonia, decreased myelination around frontal and occipital horns of the lateral 177 ventricles, spastic tetraplegia, myoclonic jerks, and opisthotonos attacks. 178 To evaluate the evidence for these VUS and propose specific functional hypotheses, we
- assessed the effects of these variants on protein expression, structure, and function with
 experimental and computational methods.
- 181
- 182 Structural modeling suggests distinct functional effects for candidate KCNC2 variants

To evaluate the potential effects of the *KCNC2* variants at the molecular level, we constructed a
 homology model of its tetrameric structure based on a high-resolution structure of the Kv1.2 Kv2.1 paddle chimera channel (PDB ID: 2R9R) ⁴² using the Rosetta molecular modeling suite
 (Methods) ⁴⁹.

187 The homo-tetrameric Kv3.2 model, with six transmembrane helical domains (S1-S6) is 188 shown in Figure 1A. The PVP motif ranges between residues 468 and 470 on the S6 helix and 189 facilitates channel gating. The variants of interest p.V469L and p.V471L are adjacent to the PVP 190 motif (Figure 1B). The channel pore is formed by the S5 and S6 helices of all four chains 191 together (Figure 1C), and the PVP motifs on all four helices act together for channel gating. 192 This region is almost entirely conserved among vertebrates (Figure S1A). Furthermore, 193 previous studies have shown that altering the central hydrophobic residues in Kv1.1 channels 194 from valine to isoleucine affects channel kinetics, stability, and conformational dynamics ⁵⁰.

195 The UDN subject's variant (p.V469L) results in a conservative substitution, which 196 changes the hydrophobic valine at the core of the PVP motif to leucine, another hydrophobic 197 amino acid. However, the p.V469L variant is predicted to have a deleterious effect on the 198 protein by commonly used variant effect prediction tools like CADD and GERP (Figure S1B). 199 The residue at position 469 faces into the channel pore (Figure 1D), and while conservative 200 amino acid substitutions do not usually have severe effects, in this case, the bulkier leucine 201 amino acid (Figure 1E) at the center of the PVP motif on the hinge domain could influence ion 202 transfer. We hypothesize that it could sterically obstruct the pore resulting in a decreased pore 203 radius and slower kinetics of channel gating. The steric hindrance of the curving of the S6 helix 204 could lead to fewer ions passing though the pore.

205 The second recently reported candidate KCNC2 variant ²⁹ (p.V471L) is immediately 206 adjacent to the PVP motif (Figure 1A); however, the structural context of this variant in our 207 model suggests potentially different effects from that of our UDN subject's p.V469L variant. 208 Residue p.V471 faces away from the pore (Figure 1D), and therefore, the substitution of the 209 bulkier amino acid leucine (Figure 1E) is less likely to lead to a decrease in the pore radius as 210 the residue faces outward. In this case, we hypothesize that the molecular effect of the p.V471L 211 variant would widen the pore and increase its tendency to remain open, leading to more ions 212 passing through than normal and thus a gain-of-function phenotype. We also predict that the 213 channel gating will be affected by the bulkier leucine residue; however, not to the extent of the 214 p.V469L variant since p.V471L faces away from the channel pore.

215

216 V469L causes loss of channel function, while V471L causes gain of function

217 To quantify the effects of the candidate variants we quantified the electrophysiological function

- of Kv3.2, potassium channel currents for WT Kv3.2 and the two disease causing variants
- 219 (p.V469L and p.V471L) in CHO cells. The proteins were expressed in a homo-tetrameric model,
- with all four chains carrying the variant, in each case. The WT form of Kv3.2 showed a very fast
- deactivation, in accordance with previously characterized behavior of the Kv3.2 channel (Figure
- 222 **2A, S2**). *KCNC2* is primarily expressed in the brain, where its product Kv3.2 contributes to the
- fast repolarization of action potentials in neurons of the central nervous system ^{35,51,52}.
- 224 Therefore, short spike duration and rapid deactivation of Kv3.2 channels are important for
- 225 normal physiology.

226 The electrophysiological profiles for the p.V469L variant (Figure 2B, S2) compared to 227 the WT Kv3.2 had a lower peak current and much longer deactivation tails. The peak current for 228 the p.V469L mutant was less than half that of WT (Figure 2D), with a much slower deactivation 229 and a slight negative shift of ~10mV (Figure 2E). In contrast, the electrophysiological profile for 230 p.V471L (Figure 2C, S2) showed a much higher peak current than WT, with a longer 231 deactivation tail. The p.V471L peak current was 1.5 times that of the WT channel (Figure 2D), 232 with a moderately slower deactivation, but a drastic negative shift of ~28mV (Figure 2E). The 233 very slow deactivation and slightly negative voltage shift observed for p.V469L and moderately 234 slow deactivation and dramatically negative voltage shift for p.V471L align with the structural 235 hypothesis of loss-of-function and gain-of-function phenotypes, respectively. For each variant, 236 the same amount of plasmid was injected, and the behavior of the proteins at their native levels 237 of expression was analyzed.

We further characterized the effect of the variants on channel function by administration of the voltage-gated potassium channel blocker 4-aminopyridine (4-AP). Kv3.2 is very sensitive to 4-AP ^{53–55}. 4-AP is known to approach the channel lumen from the cytoplasmic side ^{53,56,57}; and bind the open channel weakly. Once bound, the channel becomes biased towards the closed state ⁵⁶, and 4-AP binds strongly to the closed conformation, blocking the channel.

Interestingly, 4-AP blocked the channel activity similarly for the WT and p.V469L Kv3.2
(Figure 2F, S3). Both experienced >70% decreases in activity (p > 0.05, n=6). In contrast, the
gain-of-function p.V471L variant was resistant to 4-AP compared to WT and p.V469L (p <
0.0001 for both, n=6), showing a less than 30% reduction in activity (Figure 2F, S3). This could
be due to the V471L variant stabilizing the channel in the open conformation, thereby making 4AP less effective in closing the channel and less likely to bind. These results further support the
contrasting loss- and gain-of-function mechanisms we propose for p.V469L and p.V471L.

250

251 V469L expression is lower while V471L expression is higher than wild type

Rare pathogenic protein-coding variants, in addition to causing changes to protein structure and
molecular function, can also lead to altered protein expression in cells. We compared the levels
of protein present in cells for the WT and two Kv3.2 variants with an Immunoblot analysis
(Western Blot).

256 The homomeric V469L Kv3.2 was present at less than half the amount for homomeric 257 WT, while the levels for homomeric V471L Kv3.2 were greater than one and a half times that of 258 WT (Figure 3). Thus, expression differences likely contribute to the loss- and gain-of-function 259 effects for the two variants, respectively. However, while the expression levels could cause the observed differences in the peak currents for the two variants (Figure 2), differences in protein 260 261 levels alone cannot explain the slowed deactivation dynamics of the V469L channel. Thus, both 262 differences in the molecular function and expression levels of these KCNC2 variants contribute 263 to their phenotypic effects.

264

V469L constricts the channel pore in molecular dynamics simulations increasing the energetic barrier for K⁺ ion permeation

- 267 To explore the molecular basis for the functional changes caused by V469L and V471L, we
- 268 performed molecular dynamics simulations of these ion channel variants and of WT Kv3.2 in
- 269 POPC membranes. Each system was simulated for more than 1µs in total. Figure 4A-C

270 displays simulation snapshots of the three ion channel systems and Videos V1-V6 show

- 271 representative MD trajectories. We observed that the inner pore helices in V469L moved closer
- together at their hinge motif sites such that the pore became more constricted and fewer water
- 273 molecules were able to enter the inner channel cavity through the cytosolic gate. This effect was
- most likely driven by increased attractive interactions between leucine 469 residues on adjacent
- and opposite S6 helices that led to a 'de-wetting' of the channel pore. Calculation of the pore
 radius along the channel axis (z-axis) (Figure 4D) confirmed that the K⁺ ion permeation
- pathway in the V469L channel is more constricted compared to WT and V471L Kv3.2 channels.
- 278 Furthermore, we noticed small but distinct differences of the backbone structure at 279 residue 469 and preceding residues (Figure S4, Table T1). By contrast, the pore radius of the 280 V471L channel was slightly wider than that of WT Kv3.2 indicating that V471L adopted a stable 281 open conformation in MD. One possible explanation for this observation is the difference in the 282 types of interactions made by residues at positions 469 and 471. While L469 side chains are 283 oriented towards each other and towards the pore, L471 residues are oriented outward and 284 interact with residues on S5 in the same subunit and with residues on S6 in a neighboring 285 subunit. The largest number of atom contacts of L471 are made with Y480 on an adjacent S6 286 helix (Figure S5). In the variant, the number of heteroatom contacts (within 4Å radius) for the 287 L471-Y480 interaction more than doubled relative to the V471-Y480 interaction in WT Kv3.2 288 (average of ~3.2 contacts in WT Kv3.2 to ~7.0 contacts in the V471L channel). This finding 289 offers a plausible explanation for how this amino acid change at position 471 leads to 290 stabilization of the open channel conformation.
- 291 To assess the energetic cost more directly for K⁺ ion permeation in WT Kv3.2 and both 292 channel variants, we used umbrella MD simulations and calculated the potential of mean force 293 (PMF) for moving a K⁺ ion from the cytosolic site of the channel through the S6 helix gate into 294 the water-filled cavity below the selectivity filter (Figure 5A). Compared to WT, the energetic 295 barrier for ion transfer of the V469L variant increased by ~0.8 kcal/mol (Figure 5B). The V471L 296 variant, however, required an energy for ion transfer similar to WT. The highest peak in the PMF 297 and the V469L-specific energy increase occurred at position P470. This indicates that V469L, 298 but not V471L, constricts the channel pore at the PVP hinge region, which is in line with our 299 pore radius measurements.
- In summary, MD simulations provided detailed insight into the molecular mechanism
 underlying the altered function of both variants. Our MD results agree well with the
 experimentally observed loss-of-function and gain-of-function phenotypes for V469L and V471L,
 respectively.
- 304

305 DISCUSSION

- 306 Deriving actionable information for patient diagnosis and treatment from clinical sequencing
- 307 data is a fundamental challenge in genetics and medicine. Current methods for analyzing
- 308 sequencing data often fail due to the inability to predict the effects of the detected VUS on
- 309 protein function. Here, we illustrate the power of a "personalized structural biology" pipeline that
- 310 places candidate VUS into 3D structural models tailored to the patient. The integration of cycles
- of computational and experimental analysis enabled us to provide mechanistic molecular
- 312 insights into the different mechanisms by which two proximal candidate *KCNC2* VUSs lead to
- 313 DEE-like phenotypes. DEE has been previously linked to dysfunction of other ion channels 58,59.

Moreover, Kv3 channel family members have been previously associated with neurological disorders such as ataxias, epilepsies, schizophrenia, and Alzheimer's disease ⁶⁰.

The V469L variant occupies the central hydrophobic residue of the PVP motif and the 316 flexibility of this hinge region is critical for channel opening and closing kinetics ⁶¹. Previous 317 318 studies in other channels supported this hypothesis, as altering the central hydrophobic residues in Kv1.1 channels from valine to isoleucine, a constitutional isomer of leucine, affected 319 channel kinetics, stability, and conformational dynamics ⁵⁰. The V469L variant resulted in > 50% 320 321 decrease in peak current and a very slow deactivation with a slight negative shift (~10mV). 322 Interestingly, the V469L variant caused the Kv3.2 channel to be expressed at < 50% of WT. 323 Molecular dynamics simulations showed that the V469L variant had a smaller pore radius and a 324 higher energetic barrier to jon transfer. The constriction was likely the result of hydrophobic 325 interactions between bulkier L469 residues causing part of the channel pore to become devoid 326 of water molecules ^{62,63}.

327 The V471 variant is immediately adjacent to the PVP hinge motif and resulted in a > 328 50% increase in the peak current, with moderately slow deactivation, but a drastic negative shift 329 (~28mV). There was also an increase in protein expression to > 150% of WT and the pore 330 remained fully open in MD and the pore radius for the V471L variant of Kv3.2 channel was 331 slightly wider. An increased number of inter-subunit contacts made by V471L suggests a 332 possible mechanism how this mutant could selectively stabilize the open channel state. The 333 V469L and V471L variants had opposite loss-of-function and gain-of-function effects 334 respectively.

The lower current for V469L versus higher for V471L compared to WT could be 335 336 explained by the differences in protein expression levels. However, alterations in the protein 337 level would not cause changes in the kinetics of deactivation. The two variants could affect the 338 energy required for the protein to undergo conformational changes between the open and 339 closed states. The adjacency of the variants to the PVP motif would lead to changes to the 340 ability of the helix to kink at the hinge domain and facilitate channel gating. The V469L variant, 341 which results in the central hydrophobic valine of the PVP motif to be substituted by a bulkier 342 leucine extending into the pore, results in a lower tendency for the helix to kink, and therefore, 343 leads to slower channel gating and slower deactivation. In contrast, the stabilization of the 344 V471L channel in the "open" conformation, which would also affect channel gating, is consistent 345 with its moderately slow deactivation. Thus, our results indicate that the variants influence both 346 expression and channel function. However, our results do not identify the cause of the 347 differences in the expression levels of the two variants. It is likely that these result from 348 differences in protein folding or stability. Further studies, such as analysis of protein trafficking in 349 cells, are needed to identify the causes. For experimental simplicity, we carried out our in vitro 350 and in silico analyses with all four chains carrying the variant of interest. In the future, it would 351 be valuable to evaluate the spectrum of effects for channels carrying different combinations of 352 variant and WT chains; though, we anticipate similar effects.

We have not simulated the entire dynamics involved in channel activation and deactivation. This process is too long to be studied by conventional MD methods. Enhanced MD protocols, which aim at representing the free energy landscape of the molecular system by a set of low-dimensional collective variables, have been used to simulate conformational changes for some ion channel systems ⁶⁴. These methods could be helpful for explaining the observed

changes in activation potential and deactivation time. However, no general protocol for deriving
a set of collective variables that capture the whole activation and deactivation cycle of Kv
channels like Kv3.2 is available yet.

361 The ability of the channel blocker 4-AP to inhibit the V469L Kv3.2 channel aligned with the loss-of-function phenotype because 4-AP approaches the channel lumen from the 362 cytoplasm ^{53,56,57}; therefore the steric hinderance of the pore cavity by V469L should not affect 363 364 its mechanism of action. Furthermore, the decreased ability of 4-AP to block the V471L channel 365 supports the gain-of-function hypothesis. Channel closing is destabilized in V471L, so 4-AP may 366 not bind as efficiently to the open channel. These results also illustrate how the personalized 367 structural biology approach can help evaluate the effects of possible pharmacological 368 interventions. For example, 4-AP is not likely to help individuals with the V469L variant, it is 369 possible that it could counteract some effects of the V471L variant.

370 Taken together, the clinical features of our UDN and the reported and the combined 371 experimental and molecular modeling of their de novo KCNC2 variants prove their functional 372 role as a cause of DEE. The phenotypes associated with the two variants in KCNC2 are the 373 result of two fundamentally different molecular mechanisms, even though the residues are only 374 two amino acids away. Analyses of these variants in their structural context was key to revealing 375 their mechanistic and functional heterogeneity. In addition to the contribution to diagnosis, our 376 results also suggest that drugs that modulate the activity of Kv3.2 could be potential treatments. 377 This case study demonstrates the strength of personalized structural biology as a diagnostic 378 method to predict precise molecular hypotheses by taking the context of the variant if interest in 379 the 3D structure of the protein into account. Going forward, this approach has broad applicability 380 across VUS observed in studies from rare disease to cancer.

381

382 METHODS383

384 Structural modeling of Kv3.2

The tetrameric structural model of human Kv3.2 (UniProtKB accession number: Q96PR1-1, 385 modeled residues: 1-484) was generated by homology modeling using the molecular modeling 386 387 software suite Rosetta (version 3.10)⁶⁵. The shaker family voltage dependent potassium channel (Kv1.2-Kv2.1 paddle chimera channel) resolved to 2.4 Å (PDB ID: 2R9R) was used as 388 389 a template. The percent identity between the aligned positions of the sequences of Kv3.2 and 390 the template structure was 42.8%, sufficiently high for the chimera channel structure to serve as 391 a reliable template. A starting partial tetrameric model of Kv3.2, which only covered aligned 392 residues, was generated by threading the sequence of Kv3.2 onto the template structure using 393 the corresponding sequence alignment as a guide. Full models were created using the Rosetta comparative modeling (RosettaCM) protocol ⁶⁶ guided by the RosettaMembrane energy function 394 ⁶⁷ in a C4 symmetry mode ⁶⁸. The boundaries of membrane-spanning segments were calculated 395 using the PPM server ⁶⁹ based on the starting model. The boundaries were used to impose 396 397 membrane-specific Rosetta energy terms on residues within the theoretical membrane bilayer. 398 A total of 1000 full tetrameric models were generated using RosettaCM. The lowest-energy 399 model was selected as the final model for structure-based analysis in this work.

400

401 MD system setup

402 The Kv3.2 channel domain (residues L211 – M484) was embedded in a POPC (palmitoyloleoyl-403 phosphatidylcholine) bilayer (~240 lipid molecules per leaflet) using the membrane builder tool 404 of CHARMM-GUI ⁷⁰. The system was solvated in TIP3P water containing 0.15 M of neutralizing 405 KCI. Three K⁺ ions were placed in the channel selectivity filter at coordination sites S0, S2, and

406 S4 by inferring their positions from the crystal structure of the Kv1.2-2.1 chimeric channel (PDB:

407 2R9R)⁴³. Another K⁺ ion was placed below the selectivity filter in the aqueous channel cavity

- 408 (termed SCav site) and used for running umbrella simulations. During conventional MD
- 409 simulations, the position of the cavity K^{+} ion was constrained by imposing distance restraints to
- 410 the selectivity filter residue T437.
- 411
- 412 Conventional MD simulations

413 MD simulations of the Kv3.2 channel in POPC membranes were performed with AMBER16⁷¹

- using the ff14SB force field for proteins ⁷² and the Lipid17 force field. The system was simulated
- 415 in four replicas with a total simulation time of ~1 μ s. Bonds involving hydrogen atoms were

416 constrained with SHAKE ⁷³. Nonbonded interactions were evaluated with a 10 Å cutoff, and

- 417 long-range electrostatic interactions were evaluated by the particle-mesh Ewald method ⁷⁴.
- Each MD system was first minimized using a four-step energy minimization procedure:
- 419 Minimization of only lipids was followed by minimization of only water + ions, and minimization 420 of protein before the whole system was minimized. With protein and ions restrained to their
- 421 initial coordinates, the lipid and water were heated to 50 K over 1000 steps with a step size of 1
- 422 fs in the NVT ensemble using Langevin dynamics with a rapid collision frequency of 10,000 ps⁻¹.
- The system was then heated to 100 K over 50,000 steps with a collision frequency of 1000 ps^{-1} and finally to 310 K over 200,000 steps and a collision frequency of 100 ps^{-1} . After changing to the NPT ensemble, restraints on protein and ions were gradually removed over 500 ps. The
- system was equilibrated for another 10 ns at 310 K with weak positional restraints (with a force
 constant of 5 kcal mol⁻¹ Å⁻²) applied to protein Cα atoms. The protein restraints were then
 gradually removed over 20 ns, and production MD was conducted for 260 ns using a step size
 of 2 fs, constant pressure periodic boundary conditions, anisotropic pressure scaling, and
- 430 Langevin dynamics.

Subsequent to running production MD, molecules were reimaged back into the
simulation box using CPPTRAJ ⁷⁵ and the final 200 ns of each MD replica were analyzed. The
Kv3.2 channel was aligned to the first MD frame and the channel pore radius was measured
with HOLE ⁷⁶ by taking conformations of Kv3.2 at every 1 ns.

435

436 Umbrella MD simulations

437 In order to estimate the free energy of K⁺ ion permeation through the cytosolic gate of Kv3.2 438 WT, V469L, and V471L channels, we calculated the potential of mean force (PMF) of moving a 439 K⁺ ion up the pore axis past the cytosolic constriction site and into the cavity below the 440 selectivity filter. The center of mass of the backbone atoms of the selectivity filter residues (T437 441 – Y440 of all four subunits) was defined as the origin of the pore axis. Umbrella potentials (with 442 a spring constant of 10 kcal mol⁻¹ Å⁻²) were placed at 0.5 Å intervals in the range from Z = -11 Å

- 443 (below selectivity filter) to Z = -44 Å (in cytosol), making a total of 67 umbrella simulations for
- 444 each 1D PMF. In addition, to ensure that the K^+ ion remained in the vicinity of the pore axis
- 445 when it was no longer constrained by the S6 helices (i.e., was in bulk solvent), we used a

method described in Fowler et al.⁷⁷ and applied a flat-bottomed cylindrical constraint with a 446 radius of 8 Å and a spring constant of 10 kcal mol⁻¹ Å⁻². Starting configurations for each umbrella 447 window were prepared by taking the last frame from the conventional MD simulation and 448 449 gradually pulling the cavity K⁺ ion from SCav into cytosolic solvent over 10 ns using a spring constant of 10 kcal mol⁻¹ Å⁻². To ensure that the direction of the pore axis was well-defined and 450 did not change during the simulation, the positions of the backbone atoms of the first two helix 451 452 turns of S6 (W448 – G454) were constrained by a harmonic potential with a force constant of 5 kcal mol⁻¹ Å⁻² during the pulling and umbrella simulations. Each umbrella simulation was run for 453 454 10 ns and repeated twice for each of the original four MD replicas. The WHAM method ⁷⁸ as implemented in the program by Grossfield ⁷⁹ was used to remove the umbrella biases and 455 calculate 1D PMFs. A final 1D PMF was calculated for Kv3.2 WT, V469L, and V471L, 456 457 respectively, by averaging the individual PMFs for each variant, and the height of the free 458 energy barrier relative to the bulk solvent was measured. 459

Heterologous expression of Kv3.2 ion channel and whole-cell voltage clamp electrophysiology
Wild-type Kv3.2, V469L, and V471L channel plasmids (1 ng/µl for each plasmid) were
separately transfected with fluoresced green protein (GFP as marker to identify successful ion
channel expression) into Chinese Hamster Ovary (CHO) cells using 10 µl Fugene 6 (Promega),
following manufacturer's cell transfection instructions. Two days post transfection, cells with
green color were selected for patch clamp experiments.

- 466 Whole-cell voltage clamp experiments were performed at room temperature (22-23°C) 467 with $3\sim 5 \text{ m}\Omega$ patch microelectrodes, by using a MultiClamp 700B amplifier and DigiData 1550B 468 low-noise data acquisition system (Molecular Devices Inc., Sunnydale, California). The 469 extracellular solution contained (in mmol/L) NaCl 145, KCl 4.0, MgCl₂ 1.0, CaCl₂ 1.8, glucose 470 10, and HEPES 10; the pH was 7.4, adjusted with NaOH. The pipette (intracellular) solution contained (in mmol/L) KCI 110, MgCl₂ 1.0, ATP-K₂ 5.0, BAPTA-K4 5.0, and HEPES 10; the pH 471 472 was 7.2, adjusted with KOH. Data acquisition was performed using pClamp 10.7 software 473 (Molecular Devices Inc.), sampling at 1 kHz and low-pass-filtered at 5 kHz. Activating current 474 was elicited with 1-second depolarizing pulses from a holding potential of -80 mV at a 10-mV 475 increments, and tail current was recorded on return to -40 mV. The voltage-clamp protocol is 476 shown in Figure EP. Pulses were delivered every 15 seconds. The current-voltage (I-V) 477 relationships were analyzed by fitting the Boltzmann equation to the data:
- 478 $I=I_{max} / \{1 + \exp[(V_t V_{0.5}) / k]\}$, where I_{max} is the maximal current, V_t is the test potential, $V_{0.5}$ is 479 the membrane potential at which 50% of the channels are activated, and k is the slope factor. 480 Current densities (pA/pF) were obtained after normalization to cell surface area calculated by
- the Membrane Test in pClamp 10.7. A potassium channel blocker 4-aminopyridine (4-AP at 200
- 482 μM; Sigma-Aldrich Co., St. Louis, MO, USA) was used to test the sensitivity of wildtype Kv3.2
- and two variant (V469L and V471L) channels to drug block by 1-second repetitive pulsing
- 484 protocol from a holding potential of -80 mV to a testing potential of +60 mV (Figure S3).
- 485
- 486 DNA constructs for WT and variants of KCNC2
- 487 The coding sequences DNA of human *Homo sapiens* potassium voltage-gated channel
- 488 subfamily C member 2 *KCNC2* (NM_139137.4)) was subcloned into pcDNA3.1+ /C-(k)-DYK
- 489 expression vector with an equipped Flag tag (DYKDDDDK) in C-terminal (GenScript, NJ, USA).

- 490 The mutant KCNC2 variants Kv3.2-V469L and Kv3.2-V471L cDNA constructs were generated
- 491 by using a pair of designed overlapping primers for the PCR in the QuikChange Site-Directed
- 492 Mutagenesis Kit (Agilent USA Cat. # 200523) and by PCR Overlap Extension method to
- 493 introduce the mutation site in. Both variants were confirmed by DNA sequencing.
- 494
- 495 Western Blot
- 496 To detect the Kv3.2 protein expression and to perform protein functional analysis, the wild type
- 497 and two mutated cDNA plasmids were transfected to CHO stable cells (ATCC, USA) by X-
- 498 tremeGENE 9 DNA Transfection Reagent (Roche). The transfected cells were collected and
- 499 lysed in modified Radio-Immunoprecipitation Assay (RIPA) lysis buffer (50 mM Tris pH = 7.4,
- 500 150mM NaCl, 1% NP-40, 0.2% Sodium Deoxycholate, 1mM EDTA), and 1% protease inhibitor 501 cocktail (Sigma-Aldrich Co., USA). Collected protein samples were subjected to gel
- 502 electrophoresis using 4–12% BisTris NuPAGE precast gels (Invitrogen Life Technologies, USA)
- 503 and transferred to PVDF-FL membranes (MilliporeSigma, USA). Primary antibody against Flag
- 504 epitope tag located on FLAG fusion proteins (Sigma-Aldrich, polyclonal ANTI-FLAG, rabbit host.
- 505 F7425) was used to detect the Kv3.2 protein by indirect immunofluorescent staining at a 1:500
- 506 dilution. Anti-Na⁺/K⁺ ATPase antibody (Developmental Studies Hybridoma Bank, Antibodies at
- 507 the University of Iowa for use in research, USA) at a 1:1000 dilution was used as an internal
- 508 guality control. IRDye conjugated secondary anti-rabbit antibody (LI-COR Biosciences Inc. USA)
- 509 was used at a 1:10000 dilution. The membranes were scanned using the Odyssey Infrared
- 510 Imaging System, and the integrated density value of bands was determined using the Odyssev
- 511 Image Studio software (LI-COR Biosciences Inc. USA).
- 512
- 513 Clinical Report
- 514 Please contact the corresponding authors for clinical details.
- 515

516 ACKNOWLEDGEMENTS

- 517 First, we thank all affected UDN individuals and their families. We thank members of the Capra, 518 Meiler, and UDN Labs for helpful comments. This work was conducted in part with the 519 resources of the Advanced Computing Center for Research and Education at Vanderbilt University, Nashville, TN.
- 520
- 521

522 FUNDING

- 523 This work was supported by awards from The National Institutes of Health (NIH) Common Fund, 524 through the Office of Strategic Coordination and the Office of the NIH Director, to the clinical
- 525 sites (U01HG007674 to Vanderbilt University Medical Center, U01HG010215-03S1 to
- 526 Washington University). The work was also supported by NIH awards R01LM013434, and
- 527 R01GM126249. BL was supported by a fellowship from the American Heart Association.
- 528

529 **AUTHOR CONTRIBUTIONS**

- 530 Conceptualization, S.M., T.A.C., G.K., J.A.P.III, J.A.C.; Methodology, S.M., B.L., N.H., T.Y.,
- W.S., R.L.M., D.M.R., J.M., G.K., J.A.P.III, J.A.C.; Investigation, S.M., B.L., N.H., T.Y., W.S., 531
- 532 J.H.S., C.W.M., G.K.; Writing – Original Draft, S.M., T.A.C., B.L., G.K., N.H., T.Y.; Writing –
- 533 Review & Editing, S.M., B.L., G.K., J.M., J.A.P.III, G.K., J.A.C; Funding Acquisition, R.H.,
- 534 R.L.M., D.M.R., UDN, J.A.P.III, J.M., J.A.C.; Resources, J.D.C., R.H., J.H.N., R.L.M., D.M.R.,
- 535 J.M., J.A.P.III, J.A.C.; Supervision, D.C.R., R.L.M., D.M.R., J.M., G.K., J.A.P.III, J.A.C.
- 536


537 CONSORTIUM

538 Undiagnosed Diseases Network:

539 Maria T Acosta, David R Adams, Pankaj Agrawal, Mercedes E Alejandro, Patrick Allard, 540 Justin Alvey, Ashley Andrews, Euan A Ashley, Mahshid S Azamian, Carlos A Bacino, Guney 541 Bademci, Eva Baker, Ashok Balasubramanyam, Dustin Baldridge, Jim Bale, Deborah Barbouth, Gabriel F Batzli, Pinar Bayrak-Toydemir, Alan H Beggs, Gill Bejerano, Hugo J Bellen, Jonathan 542 543 A Bernstein, Gerard T Berry, Anna Bican, David P Bick, Camille L Birch, Stephanie Bivona, 544 John Bohnsack, Carsten Bonnenmann, Devon Bonner, Braden E Boone, Bret L Bostwick, 545 Lorenzo Botto, Lauren C Briere, Elly Brokamp, Donna M Brown, Matthew Brush, Elizabeth A 546 Burke, Lindsay C Burrage, Manish J Butte, John Carey, Olveen Carrasguillo, Ta Chen Peter 547 Chang, Hsiao-Tuan Chao, Gary D Clark, Terra R Coakley, Laurel A Cobban, F Sessions Cole, 548 Heather A Colley, Cynthia M Cooper, Heidi Cope, William J Craigen, Precilla D'Souza, Surendra 549 Dasari, Mariska Davids, Jyoti G Dayal, Esteban C Dell'Angelica, Shweta U Dhar, Naghmeh 550 Dorrani, Daniel C Dorset, Emilie D Douine, David D Draper, Laura Duncan, David J Eckstein, Lisa T Emrick, Christine M Eng, Cecilia Esteves, Tvra Estwick, Liliana Fernandez, Carlos 551 552 Ferreira, Elizabeth L Fieg, Paul G Fisher, Brent L Fogel, Irman Forghani, Laure Fresard, William 553 A Gahl, Rena A Godfrey, Alica M Goldman, David B Goldstein, Jean-Philippe F Gourdine, Alana 554 Grajewski, Catherine A Groden, Andrea L Gropman, Melissa Haendel, Neil A Hanchard, 555 Nichole Hayes, Frances High, Ingrid A Holm, Jason Hom, Yong Huang, Alden Huang, Rosario 556 Isasi, Fariha Jamal, Yong-Hui Jiang, Jean M Johnston, Angela L Jones, Lefkothea Karaviti, 557 Emily G Kelley, Dana Kiley, David M Koeller, Isaac S Kohane, Jennefer N Kohler, Susan 558 Korrick, Mary E Koziura, Deborah Krakow, Donna M Krasnewich, Joel B Krier, Jennifer E Kyle, 559 Seema R Lalani, Byron Lam, Brendan C Lanpher, Ian R Lanza, C Christopher Lau, Pace Laura, 560 Jozef Lazar, Kimberly LeBlanc, Brendan H Lee, Hane Lee, Roy Levitt, Shawn E Levy, Richard 561 A Lewis, Sharyn A Lincoln, Pengfei Liu, Xue Zhong Liu, Nicola Longo, Sandra K Loo, Joseph Loscalzo, Richard L Maas, Calum A MacRae, Ellen F Macnamara, Valerie V Maduro, Marta M 562 563 Majcherska, May Christine V Malicdan, Laura A Mamounas, Teri A Manolio, Rong Mao, 564 Thomas C Markello, Ronit Marom, Gabor Marth, Beth A Martin, Martin G Martin, Julian A 565 Martínez-Agosto, Shruti Marwaha, Thomas May, Jacob McCauley, Allyn McConkie-Rosell, Colleen E McCormack, Alexa T McCray, Thomas O Metz, Matthew Might, Eva Morava-Kozicz, 566 567 Paolo M Moretti, Marie Morimoto, John J Mulvihill, David R Murdock, Avi Nath, Stanley F 568 Nelson, J Scott Newberry, Sarah K Nicholas, Donna Novacic, Devin Oglesbee, James P 569 Orengo, Stephen Pak, J Carl Pallais, Christina G S Palmer, Moretti Paolo, Jeanette C Papp, 570 Neil H Parker, Jennifer E Posey, John H Postlethwait, Lorraine Potocki, Barbara N Pusey, Aaron Quinlan, Archana N Raja, Genecee Renteria, Chloe M Reuter, Lynette C Rives, Amy K 571 572 Robertson, Lance H Rodan, Jill A Rosenfeld, Robb K Rowley, Maura Ruzhnikov, Ralph Sacco, 573 Jacinda B Sampson, Susan L Samson, Mario Saporta, Judy Schaechter, Timothy Schedl, Kelly 574 Schoch, Darvl A Scott, Lisa Shakachite, Prashant Sharma, Vandana Shashi, Kathleen Shields, 575 Jimann Shin, Rebecca H Signer, Catherine H Sillari, Edwin K Silverman, Janet S Sinsheimer, 576 Kathy Sisco, Kevin S Smith, Lilianna Solnica-Krezel, Rebecca C Spillmann, Joan M Stoler, 577 Nicholas Stong, Jennifer A Sullivan, Shirley Sutton, David A Sweetser, Holly K Tabor, Cecelia P 578 Tamburro, Queenie K-G Tan, Mustafa Tekin, Fred Telischi, Willa Thorson, Cynthia J Tifft, 579 Camilo Toro, Alyssa A Tran, Tiina K Urv, Matt Velinder, Dave Viskochil, Tiphanie P Vogel, 580 Colleen E Wahl, Melissa Walker, Nicole M Walley, Chris A Walsh, Jennifer Wambach, Jijun Wan, Lee-Kai Wang, Michael F Wangler, Patricia A Ward, Katrina M Waters, Bobbie-Jo M 581 582 Webb-Robertson, Daniel Wegner, Monte Westerfield, Matthew T Wheeler, Anastasia L Wise, 583 Lynne A Wolfe, Jeremy D Woods, Elizabeth A Worthey, Shinya Yamamoto, John Yang, 584 Amanda J Yoon, Guoyun Yu, Diane B Zastrow, Chunli Zhao, Stephan Zuchner. 585

586 FIGURES

587



588

589

590 **Figure 1: Candidate pathogenic variants in** *KCNC2* are nearby, but have different 591 structural contexts in Kv3.2.

592 (A) Homo-tetrameric structure of Kv3.2. The complete structural model of Kv3.2 (*KCNC2*) was

593 generated using RosettaCM from Kv1.2-Kv2.1 paddle chimera channel (PDB ID: 2R9R, 42.8%

594 sequence identity). Four homologous subunits form the tetrameric channel pore structure; chain


595 A is shown in color. Each monomeric subunit has intracellular N terminal domain (black) and six

- transmembrane helical domains. S1-S4 form the voltage sensing domain (VSD, beige). The S4-
- 597 S5 linker (magenta) is the force transducer between the VSD and the channel pore, formed by


the S5 (vellow) and the S6 (red) helices. The S5-S6 linker (orange) acts as the selectivity filter, 598 599 allowing only potassium ions through the channel. The patient variant (V469L) is located in the 600 PVP motif (purple; residues 468-470) which acts a hinge domain facilitating channel gating. The 601 previously discovered variant (V471L) suspected to also cause DEE-like symptoms is located 602 adjacent to the PVP motif. (B) A view of the carbon backbone of the S6 helix, showing the PVP 603 hinge region. The valines at positions 469 (blue) and 471 (green) are shown. (C) A view of the 604 channel pore formed by the tetrameric structure of Kv3.2, showing the selectivity filter (orange) 605 and the hinge domain (purple). (D) A closer view of the channel pore with reference amino acids 606 valine at positions 469 (deep blue) and 471 (teal) shown, alongside variant leucine residues 607 (light blue and cyan). Residue 469 extends into the pore, while residue 471 faces away from the 608 pore. (E) A view of the carbon backbone of the native (valine) and substituted (leucine) amino 609 acids at positions 469 and 471.

610





613 614 Figure 2: Candidate Kv3.2 variants cause loss and gain of channel function. (A) Representative potassium current traces for wild type (WT) Kv3.2 in CHO cells recorded by 615 voltage clamp. WT shows the characteristic current amplitude and fast deactivation (short 616 617 deactivating tail currents). (B) Current traces for the V469L variant show lower peak current and 618 very slow deactivation. (C) Current traces for the V471L variant demonstrate much higher 619 current and moderately slowed deactivation compared to WT. Each voltage clamp used the 620 protocol shown in the insert of panel A. The deactivation tails are compared in greater detail in 621 Figure S2A-C. (D) Current vs. steady-state voltage (I-V) curves for WT Kv3.2, V469L, and 622 V471L. The V469L variant showed a much lower current at steady-state, while the V471L 623 variant showed increased current at steady-state. (E) Current vs. voltage plots for the tails for 624 each variant. V469L has a slight negative shift (~10 mV), while V471L has a large negative 625 voltage shift (~28 mV). Each group considered 6 to 10 cells. (F) Percentage of channel activity 626 (steady-state current) blocked by 200 µM 4-aminopyridine (4-AP), a known voltage gated potassium channel blocker, for WT, V469L, and V471L. The WT and V469L Kv3.2 were 627 similarly blocked (p > 0.05, n=6 for each), but V471L was resistant to 4-AP blockage ($p < 10^{-1}$ 628 629 0.0001, n=6). Figure S3A-C shows the protocol and representative traces for each variant. 630 Altogether, these data demonstrate loss- and gain-of-function effects on channel activity for 631 V469L and V471L, respectively. 632




634 635

636 FIGURE 3: Candidate KCNC2 variants modify Kv3.2 expression levels.

637 (A) Western blot showing expression of WT Kv3.2, V469L and V471L variants in CHO stable cells. The mock well shows only the ATPase antibody tag, while the WT, V469L and V471L 638 labeled wells have the corresponding version of Kv3.2 loaded. Kv3.2 has a molecular weight of 639 640 \sim 70 kDa and shows up as one band, below the 75 kD marker, thus confirming the presence of 641 the protein in its native state. The V471L band is larger and more intense than WT, while V469L 642 is faint. This suggests higher protein levels for V471L and lower levels for V469L compared to 643 WT. (B) Protein expression estimated from Western blot band intensity. The protein levels for 644 V469L were roughly half that of the WT, and the proteins levels for the V471L were more than 645 one and a half times that of WT. These results support a loss-of-function phenotype for V469L 646 and a potential gain-of-function phenotype for V471L.

647

648




- 650
- 651
- 652

FIGURE 4: The channel pore of Kv3.2 V469L becomes constricted in MD simulations whereas the pore of V471L adopts a stable open conformation.

655 (A) – (C) Snapshots from MD simulations of Kv3.2 WT, V469L, and V471L. The entire MD 656 trajectories are shown in Videos V1-V6. For each protein, the channel-membrane system was 657 simulated in four replicas with a total simulation time of more than 1µs. The protein is 658 represented as ribbon with each chain shown in a different color. One domain in the front is not 659 shown to better see the channel cavity. The amino acids at positions 469 and 471 are depicted 660 as spheres and colored cyan and yellow, respectively. Water molecules are shown as sticks 661 (red-white). (D) Surface representation of the pore radius of Kv3.2 WT (left) and 1D pore radius 662 profiles (right) along the channel axis (z-axis) for WT, V469L, and V471L. The solid line and 663 shaded area represent the average radius and standard deviation from four independent MD replicas.





668 669

670

FIGURE 5: V469L increases the energy required for K⁺ ion transfer through the cytosolic gate of Kv3.2 compared to WT and V471L.

673 (A) We estimated the energy required to transfer a K^+ ion (purple sphere) through the cytosolic

674 channel gate, from the bulk solvent into the cavity below the selectivity filter by umbrella MD

675 simulation. A close-up view of the gate and aqueous cavity of WT Kv3.2 channel is shown. The

subunit in the front is not depicted to better see the K⁺ permeation pathway which is lined by
residues on S6. The side chains of reference amino acids V469, P470, and V471 are drawn as

678 cyan, green, and yellow spheres, respectively. **(B)** 1D PMF of K⁺ transfer through the channel

for Kv3.2 WT, V469L, and V471L. The solid line and shaded area represent the average PMF

680 and standard deviation of four independent MD simulations. The V469L variant induces a

681 greater energetic barrier to ion transfer compared to WT and V471L. The increased energetic

requirement is focused on the conserved P470 residue in the hinge region. This supports the

relevance of the disruption of this element to function and the functional difference between

684 V469L and V471L in spite of their spatial proximity.

686 SUPPLEMENTARY FIGURES

- 687
- 688

А	×69	В		
human chimp macaque mouse	AMPVPV IVNNFGMYY AMPVPV IVNNFGMYY AMPVPV IVNNFGMYY AMPVPV IVNNFGMYY AMPVPV IVNNFGMYY	Variant	c.1405G>T (p.V469L)	c.1411 G>C (p.V471L)
rat dog cat	AMPVPV IVNNFGMYY AMPVPV IVNNFGMYY AMPVPV IVNNFGMYY	CADD	24	26.8
horse pig chicken zebrafish	AMPVPV IVNNFGMYY AMPVPV IVNNFGMYY AMPVPV IVNNFGMYY AMPVPV IVNNFGMYY	GERP	6.06	6.06

689 690

691 FIGURE S1: KCNC2 variants are located in the evolutionarily conserved hinge domain

and predicted to be deleterious.


693 (A) The amino acid sequence flanking the PVP motif (green box) and the V469L and V471L are

deeply conserved across vertebrate species. (B) V469L and V471L are both predicted to be

functional by the combined annotation dependent depletion (CADD) and genomic evolutionaryrating profile (GERP) scores.

697

699



700 701

702 FIGURE S2: Candidate *KCNC2* variants have different effects on Kv3.2 deactivation tail

703 kinetics.

704 (A) Current traces for the deactivating tails for wild type (WT) Kv3.2. The short peak indicates

fast deactivation, which is a hallmark of Kv3.2, and required for fast depolarization of membrane

potential in the central nervous system. **(B)** Current traces for the deactivating tails of V469L


707 Kv3.2 show a much slower deactivation, indicated by the long peak which does not return to

zero. (C) Current traces for the deactivating tails of V471L Kv3.2 demonstrate a much higher

current and a somewhat slowed deactivation, indicated by the higher and longer peak,

710 compared to the WT.

711



714

715

716 FIGURE S3: 4-AP differentially blocks variant Kv3.2 channels.

The effect of 4-aminopyridine (4-AP), a voltage gated potassium channel blocker, on WT Kv3.2


718 (A), V469L (B), and V471L (C) channel activity. Representative baseline (absence of 4-AP)

719 current traces are shown in black for each protein, and representative traces with 200 uM 4-AP

are shown in gray. 4-AP blocked the WT and V469L at similar levels. However, activity of the

721 V471L variant was only modestly reduced by 4-AP and maintained high activity. The voltage-

- 722 clamp protocol is shown as insert in panel A.
- 723



724

FIGURE S4: Distribution of \phi and \psi backbone angles of pore helix residues 461 to 478

- 726 sampled in MD simulation of Kv3.2 WT, V469L, and V471L.
- For Kv3.2 V469L variant, small changes are found at ψ 466, ϕ 467, ψ 468 and ϕ 469, and for
- 728 Kv3.2 V471L at ψ 466 (**TABLE T1**)
- 729
- 730

		WT	V469L	V71L			
Residue	Dihedral	median	median	median	WT - V469L	WT - V471L	V469L - V471L
463	φ	-68.214	-67.374	-67.786	0.840	0.428	0.412
	Ψ	-32.987	-35.295	-37.187	2.308	4.2	1.892
464	φ	-65.619	-64.638	-64.060	0.981	1.559	0.578
	Ψ	-36.610	-38.107	-37.833	1.497	1.223	0.274
465	φ	-78.080	-76.485	-76.110	1.595	1.97	0.375
	Ψ	-32.992	-34.092	-36.759	1.100	3.767	2.667
466	φ	-69.493	-72.195	-71.071	2.702	1.578	1.124
	Ψ	-21.215	-27.900	-28.040	6.685	6.825	0.140
467	φ	-78.686	-72.731	-75.937	5.955	2.749	3.206
407	Ψ	-54.420	-51.163	-53.854	3.257	0.566	2.691
400	φ	-76.931	-77.422	-80.585	0.491	3.654	3.163
468	Ψ	-32.838	-21.468	-30.719	11.370	2.119	9.251
469	φ	-62.922	-58.835	-61.602	4.087	1.32	2.767
	Ψ	-43.718	-43.248	-41.395	0.470	2.323	1.853
470	φ	-58.551	-60.526	-57.736	1.975	0.815	1.160
	Ψ	-31.664	-31.793	-28.719	0.129	2.945	2.816
471	φ	-70.613	-71.664	-68.606	1.051	2.007	0.956
	Ψ	-40.992	-41.250	-39.090	0.258	1.902	1.644
472	φ	-63.507	-63.709	-68.455	0.202	4.948	4.746
	Ψ	-43.176	-45.512	-41.865	2.336	1.311	1.025
473	φ	-63.365	-64.722	-63.215	1.357	0.15	1.207
	Ψ	-38.527	-38.229	-38.088	0.298	0.439	0.141
474	φ	-65.186	-65.446	-63.958	0.260	1.228	0.968
	Ψ	-36.940	-38.138	-38.796	1.198	1.856	0.658
475	φ	-70.334	-67.447	-67.946	2.887	2.388	0.499
	Ψ	-46.164	-45.022	-44.724	1.142	1.44	0.298


731

732

TABLE T1: Summary of φ and ψ backbone angles of pore helix residues 463 to 475 sampled in MD simulation of Kv3.2 WT, V469L, and V471L.

For Kv3.2 V469L variant, small changes are found at ψ and ϕ angles for several residues. The alterations for ψ 466 were consistent between both the variants, indicating a strain on the S6 helix resulting from both variants. However, the difference between V469L and WT for ψ 468 and ϕ 469 were specific for V469L variant, and not observed for the V471L variant. Conversely, the alterations to ψ 471 and ϕ 472 were observed specifically for the V471L variant, indicating these changes were specific for the position and resulting amino acid of the variants.





742 743

744 FIGURE S5: Adjacent pore helices in Kv3.2 form a contact between residues 471 and 480.

(A) Cytosolic view of structural models of Kv3.2 WT and V471L. Each subunit is shown with a
different color. V471 in WT Kv3.2 and L471 in the pV471L variant, respectively, are represented
as spheres and colored yellow. Residue Y480 is shown in cyan. (B) Close-up view of residues

- 748 V471 (left) or L471 (right) interacting with Y480.
- 749

750 **REFERENCES**

- 1. Ng, S.B., Turner, E.H., Robertson, P.D., Flygare, S.D., Bigham, A.W., Lee, C., Shaffer, T.,
- Wong, M., Bhattacharjee, A., Eichler, E.E., et al. (2009). Targeted capture and massively parallel sequencing of 12 human exomes. Nature *461*, 272–276.
- 2. Ionita-Laza, I., Makarov, V., Yoon, S., Raby, B., Buxbaum, J., Nicolae, D.L., and Lin, X.
- 755 (2011). ARTICLE Finding Disease Variants in Mendelian Disorders By Using Sequence Data:
- 756 Methods and Applications. Am. J. Hum. Genet. *89*, 701–712.
- 3. Ng, S.B., Buckingham, K.J., Lee, C., Bigham, A.W., Tabor, H.K., Dent, K.M., Huff, C.D.,
- Shannon, P.T., Jabs, E.W., Nickerson, D.A., et al. (2010). Exome sequencing identifies the
- r59 cause of a mendelian disorder. Nat. Genet. 42, 30–35.
- 4. Boycott, K.M., Rath, A., Chong, J.X., Hartley, T., Alkuraya, F.S., Baynam, G., Brookes, A.J.,
- Brudno, M., Carracedo, A., Den Dunnen, J.T., et al. (2017). COMMENTARY International
- 762 Cooperation to Enable the Diagnosis of All Rare Genetic Diseases.
- 5. Chong, J.X., Buckingham, K.J., Jhangiani, S.N., Boehm, C., Sobreira, N., Smith, J.D., Harrell,
- T.M., Mcmillin, M.J., Wiszniewski, W., Gambin, T., et al. (2015). The Genetic Basis of Mendelian
 Phenotypes: Discoveries, Challenges, and Opportunities.
- 6. Boycott, K.M., Hartley, T., Biesecker, L.G., Gibbs, R.A., Innes, A.M., Riess, O., Belmont, J.,
- 767 Dunwoodie, S.L., Jojic, N., Lassmann, T., et al. (2019). A Diagnosis for All Rare Genetic
- 768 Diseases: The Horizon and the Next Frontiers. Cell 177, 32–37.
- 769 7. Gahl, W.A., Mulvihill, J.J., Toro, C., Markello, T.C., Wise, A.L., Ramoni, R.B., Adams, D.R.,
- and Tifft, C.J. (2016). The NIH Undiagnosed Diseases Program and Network: Applications to
 modern medicine. Mol. Genet. Metab. *117*, 393–400.
- 8. Gahl, W.A., Wise, A.L., and Ashley, E.A. (2015). The Undiagnosed Diseases Network of the National Institutes of Health. JAMA *314*, 1797.
- 9. Ramoni, R.B., Mulvihill, J.J., Adams, D.R., Allard, P., Ashley, E.A., Bernstein, J.A., Gahl,
- W.A., Hamid, R., Loscalzo, J., McCray, A.T., et al. (2017). The Undiagnosed Diseases Network:
- Accelerating Discovery about Health and Disease. Am. J. Hum. Genet. *100*, 185–192.
- 10. Niroula, A., and Vihinen, M. (2016). Variation Interpretation Predictors: Principles, Types,
- 778 Performance, and Choice (John Wiley and Sons Inc.).
- 11. Tang, H., and Thomas, P.D. (2016). Tools for predicting the functional impact of
- nonsynonymous genetic variation. Genetics 203, 635–647.
- 781 12. Peterson, T.A., Doughty, E., and Kann, M.G. (2013). Towards precision medicine: Advances
- in computational approaches for the analysis of human variants. J. Mol. Biol. 425, 4047–4063.
- 13. Thusberg, J., Olatubosun, A., and Vihinen, M. (2011). Performance of mutation
- pathogenicity prediction methods on missense variants. Hum. Mutat. 32, 358–368.
- 14. Niroula, A., and Vihinen, M. (2017). Predicting Severity of Disease-Causing Variants. Hum.
 Mutat. *38*, 357–364.
- 15. Riera, C., Padilla, N., and de la Cruz, X. (2016). The Complementarity Between Protein-
- Specific and General Pathogenicity Predictors for Amino Acid Substitutions. Hum. Mutat. 37,
 1013–1024.
- 16. Grimm, D.G., Azencott, C.A., Aicheler, F., Gieraths, U., Macarthur, D.G., Samocha, K.E.,
- Cooper, D.N., Stenson, P.D., Daly, M.J., Smoller, J.W., et al. (2015). The evaluation of tools
- used to predict the impact of missense variants is hindered by two types of circularity. Hum.Mutat. 36, 513–523.
- 17. Vihinen, M. (2021). Functional effects of protein variants. Biochimie *180*, 104–120.
- 18. Niroula, A., and Vihinen, M. (2019). How good are pathogenicity predictors in detecting
 benign variants? PLoS Comput. Biol. *15*,.
- 19. Delsuc, M., Vitorino, M., and Kieffer, B. (2020). Determination of Protein Structure and
- 798 Dynamics by NMR. In Structural Biology in Drug Discovery, (Wiley), pp. 295–323.
- 20. Lyumkis, D. (2019). Challenges and opportunities in cryo-EM single-particle analysis. J. Biol.
- 800 Chem. 294, 5181–5197.

- 801 21. Murata, K., and Wolf, M. (2018). Cryo-electron microscopy for structural analysis of dynamic
 802 biological macromolecules. Biochim. Biophys. Acta Gen. Subj. *1862*, 324–334.
- 803 22. Herzik, M.A., Wu, M., and Lander, G.C. (2019). High-resolution structure determination of sub-100 kDa complexes using conventional cryo-EM. Nat. Commun. *10*, 1–9.
- 23. Gauto, D.F., Estrozi, L.F., Schwieters, C.D., Effantin, G., Macek, P., Sounier, R., Sivertsen,
- A.C., Schmidt, E., Kerfah, R., Mas, G., et al. (2019). Integrated NMR and cryo-EM atomic-
- resolution structure determination of a half-megadalton enzyme complex. Nat. Commun. 10, 1–
 12.
- 24. Ikeya, T., Güntert, P., and Ito, Y. (2019). Protein structure determination in living cells. Int. J.
 Mol. Sci. 20,.
- 25. Senior, A.W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A.,
- Nelson, A.W.R., Bridgland, A., et al. (2020). Improved protein structure prediction using
 potentials from deep learning. Nature *577*, 706–710.
- 26. Kuhlman, B., and Bradley, P. (2019). Advances in protein structure prediction and design.
- 815 Nat. Rev. Mol. Cell Biol. 20, 681–697.
- 27. Gao, W., Mahajan, S.P., Sulam, J., and Gray, J.J. (2020). Deep Learning in Protein
- 817 Structural Modeling and Design. Patterns 1, 100142.
- 28. Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F.T.,
- De Beer, T.A.P., Rempfer, C., Bordoli, L., et al. (2018). SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res. *46*, W296–W303.
- 29. Vetri, L., Calì, F., Vinci, M., Amato, C., Roccella, M., Granata, T., Freri, E., Solazzi, R.,
- 822 Romano, V., and Elia, M. (2020). A de novo heterozygous mutation in KCNC2 gene implicated
- in severe developmental and epileptic encephalopathy. Eur. J. Med. Genet. 63, 103848.
 30. Berg, A.T., Levy, S.R., and Testa, F.M. (2018). Evolution and course of early life
- developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome. Epilepsia 59,
- 826 2096–2105.
- 827 31. Berg, A.T., Mahida, S., and Poduri, A. (2021). KCNQ2-DEE: developmental or epileptic
 828 encephalopathy? Ann. Clin. Transl. Neurol. *8*, 666–676.
- 32. McTague, A., Howell, K.B., Cross, J.H., Kurian, M.A., and Scheffer, I.E. (2016). The genetic
 landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol. *15*, 304–
 316.
- 33. Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., and De Jonghe,
- P. (2001). De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am. J. Hum. Genet. *68*, 1327–1332.
- 835 34. Allen, N.M., Weckhuysen, S., Gorman, K., King, M.D., and Lerche, H. (2020). Genetic
- potassium channel-associated epilepsies: Clinical review of the Kv family. Eur. J. Paediatr.
 Neurol. 24, 105–116.
- 838 35. Rudy, B., and McBain, C.J. (2001). Kv3 channels: Voltage-gated K+ channels designed for high-frequency repetitive firing. Trends Neurosci. *24*, 517–526.
- 840 36. MacKinnon, R. (1995). Pore loops: An emerging theme in ion channel structure. Neuron *14*, 841 889–892.
- 842 37. Hidalgo, P., and MacKinnon, R. (1995). Revealing the architecture of a K+ channel pore
- through mutant cycles with a peptide inhibitor. Science (80-.). 268, 307–310.
- 38. Pascual, J.M., Shieh, C.C., Kirsch, G.E., and Brown, A.M. (1995). Multiple residues specify
- external tetraethylammonium blockade in voltage-gated potassium channels. Biophys. J. 69,428–434.
- 39. Kim, D.M., and Nimigean, C.M. (2016). Voltage-gated potassium channels: A structural
- 848 examination of selectivity and gating. Cold Spring Harb. Perspect. Biol. *8*, a029231.
- 40. Pongs, O. (1993). Shaker related K channels. Semin. Neurosci. 5, 93–100.
- 41. Yarov-Yarovoy, V., Baker, D., and Catterall, W.A. (2006). Voltage sensor conformations in
- the open and closed states in ROSETTA structural models of K channels.

- 42. Long, S.B., Campbell, E.B., and MacKinnon, R. (2005). Voltage sensor of Kv1.2: Structural basis of electromechanical coupling. Science (80-.). *309*, 903–908.
- 43. Long, S.B., Tao, X., Campbell, E.B., and MacKinnon, R. (2007). Atomic structure of a
- voltage-dependent K+ channel in a lipid membrane-like environment. Nature 450, 376–382.
- 44. Park, J., Koko, M., Hedrich, U.B.S., Hermann, A., Cremer, K., Haberlandt, E., Grimmel, M.,
- Alhaddad, B., Beck-Woedl, S., Harrer, M., et al. (2019). KCNC1-related disorders: new de novo
- variants expand the phenotypic spectrum. Ann. Clin. Transl. Neurol. 6, 1319–1326.
- 45. Waters, M.F., Minassian, N.A., Stevanin, G., Figueroa, K.P., Bannister, J.P.A., Nolte, D.,
- Mock, A.F., Evidente, V.G.H., Fee, D.B., Müller, U., et al. (2006). Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system
- 862 phenotypes. Nat. Genet. *38*, 447–451.
- 46. Muona, M., Berkovic, S.F., Dibbens, L.M., Oliver, K.L., Maljevic, S., Bayly, M.A., Joensuu,
- T., Canafoglia, L., Franceschetti, S., Michelucci, R., et al. (2015). A recurrent de novo mutation
- in KCNC1 causes progressive myoclonus epilepsy. Nat. Genet. 47, 39–46.
- 47. Rademacher, A., Schwarz, N., Seiffert, S., Pendziwiat, M., Rohr, A., Van Baalen, A., Helbig,
- I., Weber, Y., and Muhle, H. (2020). Whole-exome sequencing in NF1-related west syndrome
 leads to the identification of KCNC2 as a novel candidate gene for epilepsy. Neuropediatrics *51*,
- 869 368–372.
- 48. Schwarz, N., Seiffert, S., Pendziwiat, M., Rademacher, A., Hedrich, U.B., Augustijn, P.B.,
- 871 Baier, H., Bayat, A., Bisulli, F., Buono, R.J., et al. (2021). Karl Martin Klein 19-21, Ioanna
- Kousiappa 22, Wolfram S. 7 Kunz 23, Holger Lerche 1, Laura Licchetta 9. Lejla
 Mulahasanovic *12*, 20.
- 49. Leaver-Fay, A., Tyka, M., Lewis, S.M., Lange, O.F., Thompson, J., Jacak, R., Kaufman, K.,
- 875 Renfrew, P.D., Smith, C.A., Sheffler, W., et al. (2011). Rosetta3: An object-oriented software
- suite for the simulation and design of macromolecules. In Methods in Enzymology, pp. 545–574.
- 50. Imbrici, P., Grottesi, A., D'Adamo, M.C., Mannucci, R., Tucker, S.J., and Pessia, M. (2009).
- 878 Contribution of the central hydrophobic residue in the PXP motif of voltage-dependent K+ 879 channels to S6 flexibility and gating properties. Channels 3, 39–45
- channels to S6 flexibility and gating properties. Channels 3, 39–45.
- 51. Rudy, B., Chow, A., Lau, D., Amarillo, Y., Ozaita, A., Saganich, M., Moreno, H., Nadal, M.S.,
- 881 Hernandez-Pineda, R., Hernandez-Cruz, A., et al. (1999). Contributions of Kv3 channels to
- neuronal excitability. In Annals of the New York Academy of Sciences, (New York Academy of
 Sciences), pp. 304–343.
- 52. Erisir, A., Lau, D., Rudy, B., and Leonard, C.S. (1999). Function of specific K+ channels in
- sustained high-frequency firing of fast-spiking neocortical interneurons. J. Neurophysiol. *82*,
 2476–2489.
- 53. Kirsch, G.E., and Drewe, J.A. (1993). Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels. J. Gen. Physiol. *102*, 797–816.
- 54. Alviña, K., and Khodakhah, K. (2010). The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J. Neurosci. *30*, 7258–7268.
- 55. Chang, K.W., Yuan, T.C., Fang, K.P., Yang, F.S., Liu, C.J., Chang, C.S., and Lin, S.C.
- (2003). The increase of voltage-gated potassium channel Kv3.4 mRNA expression in oral
 squamous cell carcinoma. J. Oral Pathol. Med. 32, 606–611.
- 56. Armstrong, C.M., and Loboda, A. (2001). A model for 4-aminopyridine action on K channels:
 Similarities to tetraethylammonium ion action. Biophys. J. *81*, 895–904.
- 57. Choquet, D., and Korn, H. (1992). Mechanism of 4-Aminopyridine Action on Voltage-gated
 Potassium Channels in Lymphocytes.
- 58. Van Hoeymissen, E., Held, K., Freitas, A.C.N., Janssens, A., Voets, T., and Vriens, J.
- 899 (2020). Gain of channel function and modified gating properties in TRPM3 mutants causing900 intellectual disability and epilepsy. Elife 9, 1–12.
- 901 59. Crawford, K., Xian, J., Helbig, K.L., Galer, P.D., Parthasarathy, S., Lewis-Smith, D.,
- 802 Kaufman, M.C., Fitch, E., Ganesan, S., O'Brien, M., et al. (2021). Computational analysis of

- 903 10,860 phenotypic annotations in individuals with SCN2A-related disorders. Genet. Med. 23,
- 904 1263–1272.
- 905 60. Kaczmarek, L.K., and Zhang, Y. (2017). Kv3 channels: Enablers of rapid firing,
- 906 neurotransmitter release, and neuronal endurance. Physiol. Rev. 97, 1431–1468.
- 907 61. Labro, A.J., Raes, A.L., Bellens, I., Ottschytsch, N., and Snyders, D.J. (2003). Gating of
- 908 Shaker-type Channels Requires the Flexibility of S6 Caused by Prolines. J. Biol. Chem. 278, 909 50724–50731.
- 910 62. Yazdani, M., Jia, Z., and Chen, J. (2020). Hydrophobic dewetting in gating and regulation of 911 transmembrane protein ion channels. J. Chem. Phys. *153*, 110901.
- 63. Aryal, P., Sansom, M.S.P., and Tucker, S.J. (2015). Hydrophobic gating in ion channels. J. Mol. Biol. *427*, 121–130.
- 914 64. Lev, B., Murail, S., Poitevin, F., Cromer, B.A., Baaden, M., Delarue, M., and Allen, T.W.
- 915 (2017). String method solution of the gating pathways for a pentameric ligand-gated ion
- 916 channel. Proc. Natl. Acad. Sci. U. S. A. *114*, E4158–E4167.
- 917 65. Leman, J.K., Weitzner, B.D., Lewis, S.M., Adolf-Bryfogle, J., Alam, N., Alford, R.F.,
- 918 Aprahamian, M., Baker, D., Barlow, K.A., Barth, P., et al. (2020). Macromolecular modeling and
- 919 design in Rosetta: recent methods and frameworks. Nat. Methods 17, 665–680.
- 920 66. Song, Y., Dimaio, F., Wang, R.Y.R., Kim, D., Miles, C., Brunette, T., Thompson, J., and
- Baker, D. (2013). High-resolution comparative modeling with RosettaCM. Structure *21*, 1735–
 1742.
- 923 67. Barth, P., Wallner, B., and Baker, D. (2009). Prediction of membrane protein structures with
- 924 complex topologies using limited constraints. Proc. Natl. Acad. Sci. U. S. A. 106, 1409–1414.
- 925 68. DiMaio, F., Leaver-Fay, A., Bradley, P., Baker, D., and André, I. (2011). Modeling symmetric 926 Macromolecular structures in Rosetta3. PLoS One *6*, 20450.
- 927 69. Lomize, M.A., Pogozheva, I.D., Joo, H., Mosberg, H.I., and Lomize, A.L. (2012). OPM
- database and PPM web server: Resources for positioning of proteins in membranes. Nucleic
 Acids Res. 40,.
- 930 70. Wu, E.L., Cheng, X., Jo, S., Rui, H., Song, K.C., Dávila-Contreras, E.M., Qi, Y., Lee, J.,
- 931 Monje-Galvan, V., Venable, R.M., et al. (2014). CHARMM-GUI membrane builder toward
- realistic biological membrane simulations. J. Comput. Chem. 35, 1997–2004.
- 933 71. Case, D.A., Betz, R.M., Cerutti, D.S., Cheatham III, T.E., Darden, T.A., Duke, R.E., Giese,
- T.J., Gohlke, H., Goetz, A.W., Homeyer, N., et al. (2016). Principal contributors to the current
 codes : Amber 2016 Reference Manual. AMBER 2016, Univ. California, San Fr.
- 936 72. Maier, J.A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K.E., and Simmerling, C.
- 937 (2015). ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from
- 938 ff99SB. J. Chem. Theory Comput. *11*, 3696–3713.
- 939 73. Ryckaert, J.-P., Ciccotti+, G., and Berendsen, H.J.C. (1977). Numerical integration of the
- 940 Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes.941 J. Comput. Phys. 23, 321–341.
- 74. Darden, T., York, D., and Pedersen, L. (1993). Particle mesh Ewald: An N·log(N) method for
 Ewald sums in large systems. J. Chem. Phys. *98*, 10089–10092.
- 944 75. Roe, D.R., and Cheatham, T.E. (2013). PTRAJ and CPPTRAJ: Software for processing and 945 analysis of molecular dynamics trajectory data. J. Chem. Theory Comput. 9, 3084–3095.
- 946 76. Smart, O.S., Neduvelil, J.G., Wang, X., Wallace, B.A., and Sansom, M.S.P. (1996). HOLE:
- A program for the analysis of the pore dimensions of ion channel structural models. J. Mol.Graph. *14*, 354–360.
- 949 77. Fowler, P.W., and Sansom, M.S.P. (2013). The pore of voltage-gated potassium ion 950 channels is strained when closed. Nat. Commun. *4*, 1–8.
- 78. Kumar, S., Rosenberg, J.M., Bouzida, D., Swendsen, R.H., and Kollman, P.A. (1992). THE
- 952 weighted histogram analysis method for free-energy calculations on biomolecules. I. The
- 953 method. J. Comput. Chem. *13*, 1011–1021.

954 79. Grossfield, A. WHAM: the weighted histogram analysis method.